Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering

Rhea-AI Summary

Stealth BioTherapeutics Corp (Nasdaq: MITO) has successfully closed a registered direct offering of 2,844,446 American Depositary Shares (ADSs) at $1.125 each, raising approximately $3.2 million. The offering was facilitated by H.C. Wainwright & Co. The ADSs were issued under a shelf registration statement filed with the SEC. This funding aims to support the company's development of therapies for mitochondrial dysfunction, a key area of focus for the clinical-stage biotechnology firm.

Positive

• Raised approximately $3.2 million to support development efforts.

Negative

• Dilution of existing shareholders due to the issuance of new ADSs.

BOSTON, Nov. 24, 2020 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO) ("Stealth" or the "Company"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of 2,844,446 of its American Depositary Shares ("ADSs"), each ADS representing 12 ordinary shares of the Company.  The purchase price for one ADS was $1.125.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds from this offering were approximately $3.2 million.

The ADSs described above were offered pursuant to a "shelf" registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020. The ADSs were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering of the ADSs were filed with the SEC on November 20, 2020. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of ADSs may be obtained on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (646) 975-6996.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function.

Investor Relations 

Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering-301180012.html

SOURCE Stealth BioTherapeutics Inc.

FAQ

What is the purpose of Stealth BioTherapeutics' recent offering?

The offering aims to raise funds to support the company's development of therapies for mitochondrial dysfunction.

How much did Stealth BioTherapeutics raise from the ADS offering?

Stealth BioTherapeutics raised approximately $3.2 million from the offering.

What is the purchase price for the ADSs in Stealth's offering?

The purchase price for one ADS was $1.125.

Who acted as the placement agent for Stealth BioTherapeutics' offering?

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

When was the prospectus supplement for the offering filed with the SEC?

The prospectus supplement was filed with the SEC on November 20, 2020.

What is the stock symbol for Stealth BioTherapeutics?

The stock symbol for Stealth BioTherapeutics is MITO.